Abstract
Hepatitis C virus (HCV) has emerged as a major viral pandemic over the past two decades, infecting 170 million individuals worldwide. Egypt has the highest prevalence of hepatitis C in the world with prevalence rates of 13%- 15% of the population. Hepatitis C is characterized with its high tendency to induce chronic progressive liver damage in the form of hepatic fibrosis, cirrhosis or liver cancer. There is no vaccine against HCV infection because our understanding of the early interactions between the virus and the host immune system is still limited. The current standard of care for patients with chronic hepatitis C, pegylated interferon alpha and ribavirin combination therapy, has improved the rate of resolution of chronic hepatitis C infection. However, many patients still do not respond to therapy or develop adverse events. Moreover, the prohibitive cost of interferon-based regimen makes them inaccessible for many patients particularly in developing countries. Understanding the host and viral factors associated with viral clearance is necessary for individualizing therapy to maximize sustained virologic response rates, prevent progression to liver disease, and increase the overall benefits of therapy with respect to its costs. Host genetic diversity seems to contribute to the outcome of each phase of the clinical spectrum of HCV infection. Genome wide studies have recently showed significant associations between a set of polymorphisms in the region of the interleukin-28B (IL28B) gene and clearance of HCV in natural infection or after pegylated interferon-alfa and ribavirin treatment. This paper synthesizes the advances in pharmacogenetics of HCV infection, including the lessons learned in Egypt to date.
Keywords: Hepatitis C virus, interleukin-28B polymorphisms, pegylated interferon and ribavirin, personalized medicine, pharmacogenetics, rational therapeutics, Schistosoma mansoni co-infections, Steatosis, Hepatic Fibrosis, Viral Kinetics
Current Pharmacogenomics and Personalized Medicine
Title: Determinants of Treatment Outcomes for Hepatitis C Infection and the Path to Personalized Medicine
Volume: 9
Author(s): Sanaa M. Kamal
Affiliation:
Keywords: Hepatitis C virus, interleukin-28B polymorphisms, pegylated interferon and ribavirin, personalized medicine, pharmacogenetics, rational therapeutics, Schistosoma mansoni co-infections, Steatosis, Hepatic Fibrosis, Viral Kinetics
Abstract: Hepatitis C virus (HCV) has emerged as a major viral pandemic over the past two decades, infecting 170 million individuals worldwide. Egypt has the highest prevalence of hepatitis C in the world with prevalence rates of 13%- 15% of the population. Hepatitis C is characterized with its high tendency to induce chronic progressive liver damage in the form of hepatic fibrosis, cirrhosis or liver cancer. There is no vaccine against HCV infection because our understanding of the early interactions between the virus and the host immune system is still limited. The current standard of care for patients with chronic hepatitis C, pegylated interferon alpha and ribavirin combination therapy, has improved the rate of resolution of chronic hepatitis C infection. However, many patients still do not respond to therapy or develop adverse events. Moreover, the prohibitive cost of interferon-based regimen makes them inaccessible for many patients particularly in developing countries. Understanding the host and viral factors associated with viral clearance is necessary for individualizing therapy to maximize sustained virologic response rates, prevent progression to liver disease, and increase the overall benefits of therapy with respect to its costs. Host genetic diversity seems to contribute to the outcome of each phase of the clinical spectrum of HCV infection. Genome wide studies have recently showed significant associations between a set of polymorphisms in the region of the interleukin-28B (IL28B) gene and clearance of HCV in natural infection or after pegylated interferon-alfa and ribavirin treatment. This paper synthesizes the advances in pharmacogenetics of HCV infection, including the lessons learned in Egypt to date.
Export Options
About this article
Cite this article as:
M. Kamal Sanaa, Determinants of Treatment Outcomes for Hepatitis C Infection and the Path to Personalized Medicine, Current Pharmacogenomics and Personalized Medicine 2011; 9 (2) . https://dx.doi.org/10.2174/187569211795508466
DOI https://dx.doi.org/10.2174/187569211795508466 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease
Infectious Disorders - Drug Targets Cytogenetic and Molecular Abnormalities in Myelodysplastic Syndrome
Current Molecular Medicine SALL4: Engine of Cell Stemness
Current Gene Therapy Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Ethanol and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Current Pharmaceutical Design The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review
Current Drug Targets Rho GTPase Effector Functions in Tumor Cell Invasion and Metastasis
Current Drug Targets Furanocoumarin A: A Novel Anticancer Agent on Human Lung Cancer A549 Cells from Fructus liquidambaris
Anti-Cancer Agents in Medicinal Chemistry Stem Cell Genetic Therapy for Fanconi Anemia – A New Hope
Current Gene Therapy In Silico Studies towards Enhancing the Anticancer Activity of Phytochemical Phloretin Against Cancer Drug Targets
Current Drug Therapy Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Pinocembrin-Enriched Fractions of Elytranthe parasitica (L.) Danser Modulates Apoptotic and MAPK Cellular Signaling in HepG2 Cells
Anti-Cancer Agents in Medicinal Chemistry Lymphocyte Homing to the Liver
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents